Zytiga is the Darling of the Day. Really!

Zytiga was in news today, but more so were its competitors, Provenge and MDV3100. The big news was early unblinding of Zytiga trial in metastatic prostate cancer patients due to significant improvement seen in progression-free survival (PFS) and other endpoints.

The Prostate Cancer: New drugs in the post “Abiraterone-Jevtana-Provenge” world

The success of three new drugs (Abiraterone, Jevtana and Provenge) for castration-resistant prostate cancer (CRPC) this year, each targeting different pathways, and all showing an overall survival benefit, has raised the bar for those dreaming to join the club.  There is at least one riding the popularity vote, MDV3100, which may complete phase 3 next year.  Still, many struggle and plough through phase  1 and 2.  One way to understand, what may make some of them unique – and the reason they may evolve into serious competition one day – is to lay them out in separate classes or targets.  This is what I have done below.